


## D-Luciferin potassium salt

<b>Cat. No.:</b>	HY-12591B
<b>CAS No.:</b>	115144-35-9
<b>Molecular Formula:</b>	C <sub>11</sub> H <sub>7</sub> KN <sub>2</sub> O <sub>3</sub> S <sub>2</sub>
<b>Molecular Weight:</b>	318.41
<b>Target:</b>	Others
<b>Pathway:</b>	Others
<b>Storage:</b>	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

**In Vitro** H<sub>2</sub>O : 5 mg/mL (15.70 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.1406 mL	15.7030 mL	31.4060 mL
	5 mM	0.6281 mL	3.1406 mL	6.2812 mL
	10 mM	0.3141 mL	1.5703 mL	3.1406 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

**Description** D-Luciferin potassium salt is the substrate of luciferases that catalyze the production of light in bioluminescent insects<sup>[1]</sup>.

**In Vitro** D-luciferin is the natural substrate of the enzyme luciferase (Luc), that catalyzes the production of the typical yellowgreen light of fireflies. The present review covers the synthesis of D-luciferin and derivatives or analogues that are substrates or inhibitors of the luciferase from the American firefly *Photinus pyralis*, the enzyme more frequently used in techniques of in vitro and optical imaging<sup>[1]</sup>.

D-Luciferin exhibits a decrease in the measured  $K_m$  in PC3M-Luc cell lysates with a  $K_m$  of 34  $\mu$ M<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**In Vivo** Bioluminescence imaging (BLI) using the firefly luciferase (Fluc) as a reporter gene and D-luciferin as a substrate is currently the most widely employed technique. The total signal intensity is plotted against the time after D-luciferin injection to generate a time-intensity curve. In addition to the peak signal, the signals at fixed time points (5, 10, 15, and 20 min) after D-luciferin injection are determined as alternatives to the peak signal. The signal in a given time-intensity curve is normalized for the peak signal in the curve to represent the pattern of temporal changes after D-luciferin injection<sup>[3]</sup>.

Inject with 10  $\mu$ L of D-luciferin (intraperitoneally or intravenously) stock solution per gram of body weight: normally ~200  $\mu$ L for a 20 g mouse for a standard 150 mg/kg injection.

Thaw D-Luciferin (either Potassium or Sodium Salt) at room temperature and dissolve in dPBS (no calcium or magnesium)

to a final concentration of 15 mg/mL. Pre-wet a 0.22 µm filter by drawing through 5-10 mL of sterile H<sub>2</sub>O and discard water. Sterilize the D-Luciferin solution through the prepared 0.22 µm syringe filter. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

### Animal Administration <sup>[2]</sup>

Mice<sup>[2]</sup>

In vivo BLI is performed using a cooled charge-coupled device camera system (IVIS Imaging System 100) 3, 5, 7, 10, 12, 14, 19, 21, 24, and 28 days after the inoculation of HCT116-Luc cells. Mice are injected with 75 mg/kg D-luciferin in 100 µL of phosphate-buffered saline subcutaneously. Beginning 5 min after injection, dorsal luminescent images with an exposure time of 1 s are acquired sequentially at a rate of one image per min until 20 min after D-luciferin injection. Data acquisition is continued until 40 min postinjection on days 3 or 5 and until 25 min on day 7, because of the prolonged time course of light emission. Binning is 4 and the field of view is 15 cm.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Cell Death Dis. 2020 Sep 17;11(9):765.
- Biomed Pharmacother. 2019 Sep;117:109126.
- Int J Oncol. 2020 Jan.
- J Leukoc Biol. 2019 Nov;106(5):1089-1100.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Giuseppe Meroni, et al. D-Luciferin, derivatives and analogues: synthesis and in vitro/in vivo luciferase-catalyzed bioluminescent activity. ARKIVOC 2009 (i) 265-288.
- [2]. Inoue Y, et al. Timing of imaging after d-luciferin injection affects the longitudinal assessment of tumor growth using in vivo bioluminescence imaging. Int J Biomed Imaging. 2010;2010:471408.
- [3]. Rajesh Shinde, et al. Luciferin derivatives for enhanced in vitro and in vivo bioluminescence assays. Biochemistry. 2006 Sep 19;45(37):11103-12.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA